Dohmen will continue to operate under its brand and retain its leadership team.
The founder of Stagwell has claimed digital marketing agencies are undervalued because investors still fail to appreciate how much digital communications and e-commerce are going to transform the economy.
Shire considers splitting into two units; New Jersey finalizes physician-pharma gift limit; more biotech M&As expected in 2018
Takeda announces deals worth more than $1 billion; biotech and pharma investments reached $10.5 billion in 2017; prescriptions for nerve pain on the rise
CVS/Aetna deal will affect healthcare benefits; lawmakers pressure DEA to curb painkiller supply; Allergan and Richter's Vraylar sees positive results for bipolar depression
This time around the M&A moves will be much bigger in scope, promising to reconfigure the complex and fragile healthcare payer/provider/patient ecosystem.
UnitedHealth Group to buy DaVita primary care unit for $4.9 billion; Roche drug combo doubles lung-cancer survival in trial; study: FDA programs expedite drug approval
FDA approves Novo's diabetes drug; Walgreens undergoes rebranding in the wake of CVS-Aetna merger; pharma increasingly transparent about clinical trial data
CVS to buy Aetna for $69 billion; J&J buys commercial rights for biotech's experimental hypertension drug; Republicans repeal Obamacare's individual mandate
Biogen reports better-than-expected Spinraza sales; FDA to discuss opioid prescriptions with payers; UnitedHealth Group launches media review
Walgreens ends merger with Rite Aid; Biogen hires former Novartis exec as SVP of corporate affairs; FDA takes new measures to drive drug pricing competition
This and other changes in the market have created demand for new offerings, like mobile-friendly sites, video, and patient communities.
WPP creates WPP Health & Wellness; Publicis Health formalizes new name; 10 ways healthcare companies are testing Instagram
Drugmakers are becoming much more cautious with their budgets, WebMD executives said.
Pharma execs raise concerns about Trump's plans for the FDA; Merck ends study of experimental Alzheimer's drug; Amgen seeks new indication for Blincyto
Endo settles pay-for-delay charges; Trump signs order withdrawing U.S. from TPP; administration considers Patrick Soon-Shiong for healthcare role
IBM develops chip to detect early stages of cancer; Theranos plans to develop a "minilab;" Aetna and Humana to sell $117 million in assets
Groups urge disclosure of payments to nurse practitioners and physician assistants; Horizon seeks $3-billion acquisition of Depomed; Sanofi closes $245-million agreement to buy priority-review voucher
FDA advisory panel recommends Amgen's T-Vec; Teva again makes the case for a merger with Mylan; the FDA approves injection to treat double chins
Novo Nordisk's Saxenda to cost $1,000 a month; Boehringer Ingelheim's drug receives priority review; AbbVie's hep.-C treatment Viekira Pak generates $231 million in first-quarter sales
Actavis and Allergan have a $66-billion-dollar deal, Merck's Vytorin hits its endpoint, and Pfizer puts up $850 million for an experimental cancer drug.
Pfizer reportedly not interested in acquiring AZ; high deductible plans set to envelop healthcare insurance exchanges; GSK's mature drug portfolio finds a wholesale suitor.
Valeant's war for Allergan also includes a soft touch when it comes to doctors: the WSJ reports that the company is winning over professionals with trips and consulting offers.
An analyst says the $12.2B deal creates a one-stop shopping experience for hospitals.
Salix-Cosmo tax-inversion deal quashed, chronic heart failure market set to expand, rising generic drug prices get lawmakers' attention, NICE gives leukemia drug a thumbs-down, FDA has a good rep
The Chesterbrook, PA, drug manufacturer announced Monday Endo's unsolicited $2.2-billion bid undervalued the company.
Endo's timing also comes as Auxilium has committed to reorganizing and merging with Canada's QLT.
PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.
Allergan sets a shareholder voting date, Novo describes the types of acquisitions it will consider, and the AstraZeneca-Pfizer talks can now reopen.
Political furor over the recent spate of tax inversions is having little influence on how the government chooses its partners.